In lung cancer, Shen and colleagues demonstrated that IGF2BP2 permeates ECs in the microenvironmental via lung adenocarcinoma (LUAD) cell-derived exosomes, subsequently mediating the m6A modification of FLT4 to improve its stability and expression. The gene discussed is IGF2BP2; the disease is lung cancer.